X-linked Adrenoleukodystrophy: The Role of Contrast-enhanced MR Imaging in Predicting Disease Progression

References

1. Igarashi M, Schaumburg HH, Powers J, et al. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976;26:851-860

   PubMedWeb of Science
2. Singh I, Moser AB, Goldfischer S, et al. Lignoceric acid is oxidized in the peroxisomes: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleuko-dystrophy. Proc Natl Acad Sci U S A 1984;81:4203-4207

   Abstract/FREE Full Text
3. Laxo O, Contreras M, Hashmi M, et al. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrohy and adrenomyeloneuropathy. Proc Natl Acad Sci U S A 1988;85:7647-7651

   Abstract/FREE Full Text
4. ↵
   Migeon BR, Moser HW, Moser AB, et al. Adrneoleukodystrophy: evidence for X-linkage, inactivation and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A 1981; 78:5066-5070

   Abstract/FREE Full Text
5. Bezman L, Moser HW. The incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet 1998;76:415-419

   CrossRefPubMedWeb of Science
6. Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997;120:1485-1508

   Abstract/FREE Full Text
7. ↵
   Smith KD, Kemp S, Braiterman LT, et al. X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res 1999;24:511-525
8. Singh I, Moser AB, Moser HW, et al. Adrenoleukodystrophy: impaired oxidation of VLCF in white blood cells, cultured skin fibroblasts and amniocytes. Pediatr Res 1984;18:286-290

   PubMedWeb of Science
9. ↵
   Wanders RJA, van Roermund CWT, Lageweg W, et al. X-linked adrenoleuko-dystrophy: biochemical diagnosis and enzyme defect. J Inherit Metab Dis 1992;15:634-644

   CrossRefPubMedWeb of Science
10. ↵
    Schaumburg HH, Powers JM, Raine CS, et al. Adrenoleukodystrophy: a clinical and pathological study of 17 cases. Arch Neurol 1975;33:577-591

    Web of Science
11. ↵
    Powers J, Liu Y, Moser AB, et al. The inflammatory myelinopathy of adrenoleuko-dystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-643

    CrossRefPubMedWeb of Science
12. ↵
    Melhem ER, Breiter SN, Ulug AM, Raymond GV, Moser HW. Improved tissue characterization in adrenoleukodystrophy using magnetization transfer imaging. AJR Am J Roentgenol 1996;166:689-695

    PubMedWeb of Science
13. ↵
    Loes DJ, Hite S, Moser HW, et al. Adrenoleukodystrophy: a scoring method for brain MR observation. AJNR Am J Neuroradiol 1994;15:1761-1766

    Abstract/FREE Full Text
14. ↵
    Krivit W, Lockman LA, Watkins PA, et al. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis 1995;18:398-412

    CrossRefPubMedWeb of Science
15. ↵
    Powers JM. The pathology of peroxisomal disorders with pathogenetic considerations. J Neuropathol Exp Neurol 1994;54:710-719
16. Tzika AA, Ball WS Jr, Vigneron DB, et al. Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy. Radiology 1993;189:467-480

    PubMed
17. Kruse B, Barker PB, van Zijl PCM, et al. Multislice proton MR spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 1994;36:595-608

    CrossRefPubMedWeb of Science
18. Pouwels PJW, Kruse B, Korenke GC, et al. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 1998;29:254-265

    CrossRefPubMed